Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
News
Recent Posts
- Hidden immune activity can occur despite disease remission in AAV
- Acceptance is an ongoing practice in life with chronic illness
- Survival rate on kidney dialysis similar for those with, without AAV
- Initial data from trial of AAV therapy NKX019 expected this year
- Understanding the different types of fatigue that come with vasculitis